Encapsulated cell therapy - Bavarian Nordic

Drug Profile

Encapsulated cell therapy - Bavarian Nordic

Alternative Names: CapCell; CapCell/chemotherapy

Latest Information Update: 19 Mar 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bavarian Nordic
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cytochrome P-450 enzyme system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 19 Mar 2004 CapCell™ cell encapsulation technology is available for licensing worldwide (http://www.bavarian-nordic.com)
  • 23 Sep 2002 Suspended - Phase-II for Pancreatic cancer in Germany (IV-infusion)
  • 23 Sep 2002 Suspended - Phase-II for Pancreatic cancer in Switzerland (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top